Licensing rights to commercialize Caerulomycin A
Updated on Feb 24, 2009 09:55 pm IST
US based Nostrum Pharmaceuticals has obtained a worldwide licensing rights from Indian based Institute of Microbial Technology or IMTECH to develop and commercialise Caerulomycin A, and its proprietary derivatives and analogues for their novel indication and immuno-suppression. IMTECH is a constituent laboratory of the Council of Scientific and Industrial Research.
RELATED VIDEOS
Woman throws ink at CJP founder Dipke at Jantar Mantar - What really happened?
Published on Jul 18, 2026 06:31 pm IST
Muslims say ‘no’ to Friday Namaz on allotted land near Bhojshala temple?
Updated on Jul 18, 2026 10:51 pm IST
Congress, Shiv Sena & AAP tear into Modi govt over Sonam Wangchuk’s removal
Published on Jul 18, 2026 02:48 pm IST
Lord's ODI to be Rohit's last match for team India?
Published on Jul 17, 2026 03:27 pm IST
India joins elite nations with first Hydrogen-powered passenger train
Published on Jul 17, 2026 03:24 pm IST
China welcomes PNG’s Taipei closure, warns Trump to back off Cuba
Published on Jul 17, 2026 12:48 pm IST
Hi, {{name}}
Sign out
{{planName}}
{{^userSubscribed}}
{{/userSubscribed}}